Immunologic phenotype of hosts orally immunized with corneal alloantigens

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 5, 1998, Pages 744-753

  Ma, Ding ^a   Li, Xiao Yan ^a   Mellon, Jessamee ^a   Niederkorn, Jerry Y ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIBODY CONJUGATE; CHOLERA TOXIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORNEA CELL; CORNEA ENDOTHELIUM; CORNEA TRANSPLANTATION; ENDOTHELIUM CELL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KERATOPLASTY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PEYER PATCH; PHENOTYPE; PRIORITY JOURNAL;

EID: 0031969213     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Foulks GN, Niederkorn JY, Sanfilippo F. Corneal allograft rejection. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis: Mosby; 1996:435-445.
2. Zirm E. Eine erfolgreich totall keratoplastic. Albrecht von Graefes Arch Ophthalmol. 1906;64:580-593.
3. The Collaborative Cornea Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392-1403.
4. Khodadoust AA, Attarzadeh A. The late of corneal regrafts after previous rejection reaction. In: Silverstein AM, O'Connor GR, eds. Immunology and Immunopathology of the Eye. New York: Masson; 1979:167-173.
5. Sanfilippo F, Macqueen JM, Vaughn WK, Foulks GN. Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N Engl J Med. 1986;315:29-35.
6. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea. 1990;9:184-195.
7. Garside P, Mowat AM. Mechanisms of oral tolerance. Crit Rev Immunol. 1997;17:119-137.
8. Hancock WW, Sayegh MH, Kwok CA, Weiner HL, Carpenter CB. Oral, but not intravenous alloantigen prevents accelerated allograft rejection by selective intragraft TH2 cell activation. Transplantation. 1993;55:1112-1118.
9. Sayegh MH, Zhang ZJ, Hancock WW, Kwok CA, Carpenter CB, Weiner HL. Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization of skin allografts by orally administered alloantigen. Transplantation. 1992;53:163-166.
10. Carr RI, Zhou J, Ledingham D, et al. Induction of transplantation tolerance by administration or portal vein injection pretreatment of recipient with donor cells. Ann NY Acad Sci. 1996;778:368-370.
11. He Y-G, Mellon J, Niederkorn JY. The effect of oral immunization on corneal allograft survival. Transplantation. 1996;61:920-926.
12. Feder JM, Antonysamy MA, Moticka EJ. Oral administration of alloantigens enhances corneal allograft survival. [ARVO abstracts]. Invest Ophthalmol Vis Sci. 1995;36:S1010.
13. Ma D, Mellon J, Niederkorn JY. Oral immunization as a strategy for enhancing corneal allograft survival. Br J Ophthalmol. 1997;81:778-784.
14. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994;12:809-837.
15. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237-1240.
16. Fishman-Lobell J, Friedman A, Weiner HL. Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice. Eur J Immunol. 1994;24:2720-2724.
17. H2 cells are subject to high-dose oral tolerance and are not essential for its induction. J Immunol. 1995;154:5649-5655.
18. Aroeira LS, Cardillo F, DeAbuquerque DA, Vaz NM, Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand J Immunol. 1995;41:319-323.
19. Sun J-B, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by administration of myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA. 1996;93:7196-7201.
20. Marth T, Strober W, Kelsall BL. High dose oral tolerance in ovalbumin TCR-transgenic mice. J Immunol. 1996;157:2348-2357.
21. McMenamin C, Pimm C, McKersey M, Holt PG. Regulation of IgE responses to inhaled antigen in mice by antigen-specific γδ T cells. Science. 1994;265:1869-1871.
22. Heath WR, Miller JFAP. Oral tolerance: administration of autoantigens can exacerbate rather than ameliorate autoimmune disease. J NIH Res. 1997;9:35-39.
23. Blanas E, Carbone FR, Allison J, Miller JFAP, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science. 1996;274:1707-1709.
24. He YG, McCulley JP. Growing human corneal epithelium on collagen shield and subsequent transfer to denuded cornea in vitro. Curr Eye Res. 1991;10:851-863.
25. Yue BYJT, Sugar J, Gilboy JE, Elvart JL. Growth of human corneal endothelial cells in culture. Invest Ophthalmol Vis Sci. 1989;30:248-253.
26. Wilson SE, Weng J, Blair S, He Y-G, Lloyd S. Expression of E6/E7 or SV40 large T antigen-coding oncogenes in human corneal endothelial cells indicates regulated high-proliferative capacity. Invest Ophthalmol Vis Sci. 1995;36:32-40.
27. Li X-Y, D'Orazio T, Niederkorn JY. Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Immunol. 1996; 89:34-40.
28. Ogawa Y, Seyedin SM. Purification of transforming growth factors β1 and β2 from bovine bone and cell culture assays. In: Barnes D, Mather JP, Sato GH, eds. Methods in Enzymology. Vol 198. Peptide Growth Factors San Diego: Academic Press; 1991: 317-324.
29. Streilein JW, McCulley JP, Niederkorn JY. Heterotopic corneal grafting in mice: a new approach to the study of corneal alloimmunity. Invest Ophthalmol Vis Sci. 1982;23:489-500.
30. Peeler J, Matoba AY, Niederkorn JY. Corneal allografts induce cytotoxic T cell but not delayed hypersensitivity responses in mice. Invest Ophthalmol Vis Sci. 1985;26:1516-1523.
31. + Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens. J Immunol. 1986;136: 4362-4371.
32. Sun J-B, Holgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA. 1994; 91:10795-10799.
33. She S-C, Steahly LP, Moticka EJ. Intracameral injection of allogeneic lymphocytes enhances corneal graft survival. Invest Ophthalmol Vis Sci. 1990;31:1950-1956.
34. Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci. 1996;37:2700-2707.
35. Yao Y-F, Inoue Y, Miyazaki D, Hara Y, Shimomura Y, Tano Y, Ohashi Y. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice. Invest Ophthalmol Vis Sci. 1997;38:292-300.
36. Rizzo LV, Miller-Rivero NE, Chan C-C, Wiggert B, Nussenblatt RB, Caspi RR. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest. 1994; 94:1668-1672.
37. Mosmann TR. T lymphocyte subsets, cytokines, and effector functions. Ann NY Acad Sci. 1992;664:89-92.